This inventor holds 2 USPTO granted patents, plus 1 CIPO patent and 1 EPO patent. Top assignees: The United States of America, as Represented by the Secretary, Department of Health and Human Services, University of Illinois. Active years: 2019-2021.
Company Filing History:
2 out of 3,690 
2 out of 2,421 
Years Active: 2019-2021
Title: Hazem Abdelkarim: Innovator in Peptide Research
Introduction
Hazem Abdelkarim is a notable inventor based in Worth, IL (US). He has made significant contributions to the field of peptide research, particularly in the context of CCR3-mediated diseases. With a total of 2 patents, his work has the potential to impact therapeutic approaches for various medical conditions.
Latest Patents
Abdelkarim's latest patents focus on a peptide analog that inhibits CCR3-mediated diseases or conditions. This C–C chemokine receptor 3 (CCR3) peptide analog exhibits biased antagonism by binding to and inhibiting ligand-mediated signaling and chemotaxis. Additionally, it promotes the internalization and degradation of CCR3. The method of using this peptide analog aims to treat, prevent, or ameliorate symptoms associated with eosinophil- or CCR3-mediated diseases or conditions.
Career Highlights
Throughout his career, Hazem Abdelkarim has worked with esteemed institutions such as the University of Illinois and the United States Department of Health and Human Services. His research has contributed to advancements in understanding and treating diseases linked to CCR3.
Collaborations
Abdelkarim has collaborated with notable colleagues, including Steven Jules Ackerman and Fan Gao Laffey. These partnerships have further enriched his research endeavors and expanded the impact of his work.
Conclusion
Hazem Abdelkarim's innovative research in peptide analogs represents a significant advancement in the treatment of CCR3-mediated diseases. His contributions continue to pave the way for new therapeutic strategies in medicine.